Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 148
Filtrer
1.
Nat Rev Cardiol ; 18(3): 169-193, 2021 03.
Article de Anglais | MEDLINE | ID: mdl-33046850

RÉSUMÉ

Inflammatory cardiomyopathy, characterized by inflammatory cell infiltration into the myocardium and a high risk of deteriorating cardiac function, has a heterogeneous aetiology. Inflammatory cardiomyopathy is predominantly mediated by viral infection, but can also be induced by bacterial, protozoal or fungal infections as well as a wide variety of toxic substances and drugs and systemic immune-mediated diseases. Despite extensive research, inflammatory cardiomyopathy complicated by left ventricular dysfunction, heart failure or arrhythmia is associated with a poor prognosis. At present, the reason why some patients recover without residual myocardial injury whereas others develop dilated cardiomyopathy is unclear. The relative roles of the pathogen, host genomics and environmental factors in disease progression and healing are still under discussion, including which viruses are active inducers and which are only bystanders. As a consequence, treatment strategies are not well established. In this Review, we summarize and evaluate the available evidence on the pathogenesis, diagnosis and treatment of myocarditis and inflammatory cardiomyopathy, with a special focus on virus-induced and virus-associated myocarditis. Furthermore, we identify knowledge gaps, appraise the available experimental models and propose future directions for the field. The current knowledge and open questions regarding the cardiovascular effects associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are also discussed. This Review is the result of scientific cooperation of members of the Heart Failure Association of the ESC, the Heart Failure Society of America and the Japanese Heart Failure Society.


Sujet(s)
Cardiomyopathies/physiopathologie , Inflammation/physiopathologie , Myocardite/physiopathologie , Maladies virales/physiopathologie , Animaux , Antiviraux/usage thérapeutique , Auto-immunité/immunologie , Biopsie , COVID-19/physiopathologie , COVID-19/thérapie , Cardiomyopathies/diagnostic , Cardiomyopathies/immunologie , Cardiomyopathies/thérapie , Cardiomyopathie dilatée , Infections à coronavirus/immunologie , Infections à coronavirus/physiopathologie , Infections à coronavirus/thérapie , Infections à virus coxsackie/immunologie , Infections à virus coxsackie/physiopathologie , Infections à virus coxsackie/thérapie , Infections à cytomégalovirus/immunologie , Infections à cytomégalovirus/physiopathologie , Infections à cytomégalovirus/thérapie , Modèles animaux de maladie humaine , Infections à échovirus/immunologie , Infections à échovirus/physiopathologie , Infections à échovirus/thérapie , Infections à virus Epstein-Barr/immunologie , Infections à virus Epstein-Barr/physiopathologie , Infections à virus Epstein-Barr/thérapie , Érythème infectieux/immunologie , Érythème infectieux/physiopathologie , Érythème infectieux/thérapie , Infections à VIH/physiopathologie , Hépatite C/immunologie , Hépatite C/physiopathologie , Hépatite C/thérapie , Humains , Immunoglobulines par voie veineuse/usage thérapeutique , Facteurs immunologiques/usage thérapeutique , Inflammation/diagnostic , Inflammation/immunologie , Inflammation/thérapie , Grippe humaine/immunologie , Grippe humaine/physiopathologie , Grippe humaine/thérapie , Leucocytes/immunologie , Myocardite/diagnostic , Myocardite/immunologie , Myocardite/thérapie , Myocarde/anatomopathologie , Pronostic , Infections à roséolovirus/immunologie , Infections à roséolovirus/physiopathologie
2.
Circ Heart Fail ; 12(11): e005250, 2019 11.
Article de Anglais | MEDLINE | ID: mdl-31718319

RÉSUMÉ

BACKGROUND: Coxsackie-B-viruses (CVB) are frequent causes of acute myocarditis and dilated cardiomyopathy, but an effective antiviral therapy is still not available. Previously, we and others have demonstrated that treatment with an engineered sCAR-Fc (soluble coxsackievirus-adenovirus receptor fused to the carboxyl-terminus of human IgG) efficiently neutralizes CVB3 and inhibits the development of cardiac dysfunction in mice with acute CVB3-induced myocarditis. In this study, we analyzed the potential of sCAR-Fc for treatment of chronic CVB3-induced myocarditis in an outbred NMRI mouse model. METHODS: NMRI mice were infected with the CVB3 strain 31-1-93 and treated with a sCAR-Fc expressing adeno-associated virus 9 vector 1, 3, and 7 days after CVB3 infection. Chronic myocarditis was analyzed on day 28 after infection. RESULTS: Initial investigations showed that NMRI mice develop pronounced chronic myocarditis between day 18 and day 28 after infection with the CVB3 strain 31-1-93. Chronic cardiac infection was characterized by inflammation and fibrosis as well as persistence of viral genomes in the heart tissue and by cardiac dysfunction. Treatment of NMRI mice resulted in a distinct reduction of cardiac inflammation and fibrosis and almost complete elimination of virus RNA from the heart by day 28 after infection. Moreover, hemodynamic measurement revealed improved cardiac contractility and diastolic relaxation in treated mice compared with mice treated with a control vector (mean±SD; maximal pressure, 81.9±9.2 versus 69.4±8.6 mm Hg, P=0.02; left ventricular ejection fraction, 68.9±8.5 versus 54.2±11.5%, P=0.02; dP/dtmax, 7275.2±1674 versus 4432.6±1107 mm Hg/s, P=0.004; dP/dtmin, -4046.9±776 versus -3146.3±642 mm Hg/s, P=0.046). The therapeutic potential of sCAR-Fc is limited, however, since postponed start of sCAR-Fc treatment either 3 or 7 days after infection could not attenuate myocardial injury. CONCLUSIONS: Early therapeutic employment of sCAR-Fc, initiated at the beginning of the primary viremia, inhibits the development of chronic CVB3-induced myocarditis and improves the cardiac function to a level equivalent to that of uninfected animals.


Sujet(s)
Antiviraux/administration et posologie , Cardiomyopathies/traitement médicamenteux , Infections à virus coxsackie/traitement médicamenteux , Entérovirus humain B/effets des médicaments et des substances chimiques , Immunoconjugués/administration et posologie , Immunoglobuline G/administration et posologie , Myocardite/traitement médicamenteux , Récepteurs viraux/administration et posologie , Animaux , Cardiomyopathies/anatomopathologie , Cardiomyopathies/physiopathologie , Cardiomyopathies/virologie , Maladie chronique , Infections à virus coxsackie/anatomopathologie , Infections à virus coxsackie/physiopathologie , Infections à virus coxsackie/virologie , Modèles animaux de maladie humaine , Entérovirus humain B/pathogénicité , Fibrose , Mâle , Souris , Myocardite/anatomopathologie , Myocardite/virologie , Myocarde/anatomopathologie , Protéines de fusion recombinantes/effets indésirables , Fonction ventriculaire gauche , Charge virale
3.
BMJ Case Rep ; 12(8)2019 Aug 26.
Article de Anglais | MEDLINE | ID: mdl-31451462

RÉSUMÉ

Rituximab and other B cell depleting agents are increasingly used for haematological, immunological and neurological diseases. In a small minority, immunosuppression leads to increased virulence of normally mild infections. Brainstem encephalitis has been described occurring after infection from enteroviruses, more commonly in the paediatric population, but also in immunosuppressed adults. In this paper, we describe an enteroviral brainstem encephalitis in a rituximab-immunosuppressed patient. The enterovirus identified was Coxsackie A16, which has never yet been reported to cause brainstem encephalitis in an adult.


Sujet(s)
Liquide cérébrospinal/virologie , Infections à virus coxsackie , Encéphalite , Enterovirus/isolement et purification , Immunoglobulines par voie veineuse/administration et posologie , Rituximab , Adulte , Antinéoplasiques immunologiques/administration et posologie , Antinéoplasiques immunologiques/effets indésirables , Antinéoplasiques immunologiques/immunologie , Protocoles de polychimiothérapie antinéoplasique/administration et posologie , Tronc cérébral/imagerie diagnostique , Tronc cérébral/virologie , Infections à virus coxsackie/diagnostic , Infections à virus coxsackie/physiopathologie , Infections à virus coxsackie/thérapie , Cyclophosphamide/administration et posologie , Doxorubicine/administration et posologie , Encéphalite/diagnostic , Encéphalite/physiopathologie , Encéphalite/thérapie , Encéphalite/virologie , Humains , Sujet immunodéprimé , Facteurs immunologiques/administration et posologie , Lymphome folliculaire/traitement médicamenteux , Imagerie par résonance magnétique/méthodes , Mâle , Prednisone/administration et posologie , Rituximab/administration et posologie , Rituximab/effets indésirables , Rituximab/immunologie , Résultat thérapeutique , Vincristine/administration et posologie
4.
Viruses ; 11(7)2019 07 02.
Article de Anglais | MEDLINE | ID: mdl-31269669

RÉSUMÉ

Coxsackievirus-B4 (CV-B4) E2 can persist in the pancreatic ductal-like cells (Panc-1 cell line), which results in an impaired differentiation of these cells into islet-like cell aggregates (ICA). In this study, primary pancreatic ductal cells obtained as a by-product of islet isolation from the pancreas of seven brain-dead adults were inoculated with CV-B4 E2, followed-up for 29 days, and the impact was investigated. Viral titers in culture supernatants were analyzed throughout the culture. Intracellular viral RNA was detected by RT-PCR. Levels of ductal cell marker CK19 mRNA and of insulin mRNA were evaluated by qRT-PCR. The concentration of c-peptide in supernatants was determined by ELISA. Ductal cells exposed to trypsin and serum-free medium formed ICA and resulted in an increased insulin secretion. Ductal cells from five brain-dead donors were severely damaged by CV-B4 E2, whereas the virus persisted in cultures of cells obtained from the other two. The ICAs whose formation was induced on day 14 post-inoculation were scarce and appeared tiny in infected cultures. Also, insulin mRNA expression and c-peptide levels were strongly reduced compared to the controls. In conclusion, CV-B4 E2 lysed human primary pancreatic ductal cells or persisted in these cells, which resulted in the impairment of differentiation into insulin-producing cells.


Sujet(s)
Infections à virus coxsackie/virologie , Entérovirus humain B/physiologie , Cellules à insuline/métabolisme , Insuline/métabolisme , Conduits pancréatiques/virologie , Différenciation cellulaire , Cellules cultivées , Infections à virus coxsackie/métabolisme , Infections à virus coxsackie/physiopathologie , Entérovirus humain B/génétique , Cellules épithéliales , Humains , Cellules à insuline/cytologie
5.
Exp Anim ; 68(4): 549-558, 2019 Nov 06.
Article de Anglais | MEDLINE | ID: mdl-31243190

RÉSUMÉ

Apoptosis plays a crucial role in regulating cardiomyopathy and injuries of coxsackievirus B3 (CVB3)-induced viral myocarditis (VM). It has been reported that Astragaloside IV (AST-IV) from Astragalus membranaceus could inhibit apoptosis under a variety of pathological conditions in vivo or in vitro. However, the functional roles of AST-IV in CVB3-induced VM still remain unknown. Here, we found that AST-IV significantly enhanced survival for CVB3-induced mice. AST-IV protected the mice against CVB3-induced virus myocarditis characterized by the increased body weight, decreased serum level of creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH), supressed expression of Ifn-γ, Il-6 in heart, enhanced systolic and diastolic function of left ventricle. At the pathological level, AST-IV ameliorated the mice against CVB3-induced myocardial damage and myocardial fibrosis. In vitro, the results from flow cytometry showed that AST-IV significantly suppressed CVB3-induced cardiomyocytes apoptosis, which also were verified in vivo. Moreover, an increased expression of pro-apoptotic genes including FAS, FASL, cleaved caspase-8 and cleaved caspase-3 was found in CVB3-induced cardiomyocytes, while those was inhibited in cardiomyocytes treated with AST-IV. Taken together, the data suggest that AST-IV protected against CVB3-induced myocardial damage and fibrosis, which may partly attribute to supress activation of FAS/FASL signaling pathway.


Sujet(s)
Apoptose/effets des médicaments et des substances chimiques , Infections à virus coxsackie/physiopathologie , Myocardite/physiopathologie , Myocytes cardiaques/effets des médicaments et des substances chimiques , Agents protecteurs/pharmacologie , Saponines/pharmacologie , Triterpènes/pharmacologie , Animaux , Apoptose/physiologie , Astragalus membranaceus/composition chimique , Modèles animaux de maladie humaine , Entérovirus humain B/physiologie , Mâle , Souris , Souris de lignée C57BL , Myocytes cardiaques/physiologie , Répartition aléatoire
6.
PLoS One ; 12(6): e0180029, 2017.
Article de Anglais | MEDLINE | ID: mdl-28644868

RÉSUMÉ

INTRODUCTION: Coxsackievirus B3 (CVB3) is known to induce acute and chronic myocarditis. Most infections are clinically unapparent but some patients suffer from ventricular arrhythmias (VA) and sudden cardiac death (SCD). Studies showed that acute CVB3 infection may cause impaired function of cardiac ion channels, creating a proarrhythmic substrate. However, it is unknown whether low level CVB3+ expression in myocytes may cause altered cardiac electrophysiology leading to VA. METHODS: Cellular electrophysiology was used to analyze cellular action potentials (APs) and occurrence of afterdepolarizations from isolated cardiomyocytes of wildtype (WT) and transgenic CVB3ΔVP0 (CVB3+) mice. Further, we studied surface ECGs, monophasic APs, ventricular effective refractory period (VERP) and inducibility of VAs in Langendorff-perfused whole hearts. All used cardiomyocytes and whole hearts originated from male mice. RESULTS: Cellular action potential duration (APD) in WT and CVB3+ myocytes was unchanged. No difference in mean occurrence or amplitude of afterdepolarizations in WT and CVB3+ myocytes was found. Interestingly, resting membrane potential in CVB3+ myocytes was significantly hyperpolarized (WT: -90.0±2.2 mV, n = 7; CVB3+: -114.1±3.0 mV, n = 14; p<0.005). Consistently, in Langendorff-perfused hearts, APDs were also not different between WT and CVB3+ whole hearts. Within both groups, we found a heart rate dependent shortening of ADP90 with increasing heart rate in Langendorff-perfused hearts. VERP was significantly prolonged in CVB3+ hearts compared to WT (WT: 36.0±2.7 ms, n = 5; CVB3+: 47.0±2.0 ms, n = 7; p = 0.018). Resting heart rate (HR) in Langendorff-perfused hearts was not significantly different between both genotypes. Electrical pacing protocols induced no VA in WT and CVB3+ hearts. CONCLUSION: In CVB3+ mice, prolonged ventricular refractoriness and hyperpolarized resting membrane potentials in presence of unchanged APD were observed, suggesting that low level CVB3 expression does not promote VA by altered cardiac electrophysiology in this type of chronic myocarditis. These findings may suggest that other mechanisms such as chronic myocardial inflammation or fibrosis may account for arrhythmias observed in patients with chronic enteroviral myocarditis.


Sujet(s)
Infections à virus coxsackie/physiopathologie , Myocardite/physiopathologie , Myocardite/virologie , Myocytes cardiaques/physiologie , Myocytes cardiaques/virologie , Animaux , Troubles du rythme cardiaque/physiopathologie , Troubles du rythme cardiaque/virologie , Cellules cultivées , Maladie chronique , Modèles animaux de maladie humaine , Phénomènes électrophysiologiques , Rythme cardiaque/physiologie , Mâle , Potentiels de membrane , Souris de lignée C57BL , Souris transgéniques , Techniques de patch-clamp , Techniques de culture de tissus , Protéines virales/génétique , Protéines virales/métabolisme
7.
Virulence ; 8(6): 908-923, 2017 08 18.
Article de Anglais | MEDLINE | ID: mdl-27792461

RÉSUMÉ

In previous studies it was shown that inoculation of Swiss albino mice with CV-B4 E2 resulted in the production of serum IgG capable of enhancing the CV-B4 E2 infection of murine spleen cells cultures. To investigate whether such an enhancing activity of serum can play a role in vivo, we decided to study the CV-B4 E2 infection in mice exposed to successive inoculations of virus. In Swiss albino mice infected with CV-B4 E2 at the age of 21 days, anti-CV-B4 E2 neutralizing and enhancing activities of their serum peaked after 55 d. In contrast, mice inoculated at the age of 55 d expressed much lower activities. Despite the neutralizing activity of serum, CV-B4 E2 inoculated a second time to 55 day-old animals spread into the host. At the age of 72 and 89 d the levels of viral RNA and infectious particles were higher in organs of animals exposed to 2 successive infections compared with animals infected once at the age of 21 d or 55 d. In animals with 2 successive inoculations of CV-B4 E2 there was a relationship between the anti-CV-B4 E2 enhancing activity of serum and the level of viral RNA in organs and an enhancement of pathology was observed as displayed by histological analysis of pancreas and hyperglycaemia. Altogether our data strongly suggest that an anti-CV-B4 E2 enhancing activity in the host can play a role in the outcome of a secondary infection with this virus.


Sujet(s)
Anticorps bloquants/sang , Anticorps antiviraux/sang , Infections à virus coxsackie/immunologie , Infections à virus coxsackie/virologie , Entérovirus humain B/immunologie , Entérovirus humain B/physiologie , Animaux , Anticorps neutralisants/sang , Lignée cellulaire , Infections à virus coxsackie/sang , Infections à virus coxsackie/physiopathologie , Entérovirus humain B/pathogénicité , Interactions hôte-pathogène , Humains , Hyperglycémie , Souris , Tests de neutralisation , Pancréas/anatomopathologie , Pancréas/virologie , ARN viral , Rate/anatomopathologie , Rate/virologie , Charge virale
8.
Arch Virol ; 161(8): 2197-205, 2016 Aug.
Article de Anglais | MEDLINE | ID: mdl-27224983

RÉSUMÉ

Autophagy is an intrinsic cellular process that can degrade cytoplasmic components. It has been reported that several pathogens hijack this process to facilitate their replication. Coxsackievirus B3 (CVB3), a member of the family Picornaviridae, induces autophagy upon infection. However, the details of CVB3-induced autophagy remain a subject of debate. This study applied a combination of multiple assays for the measurement of autophagy and demonstrated that CVB3 induces a complete autophagic flux. Experiments with infected HEK293A cells revealed that autophagosomes were induced upon CVB3 infection. Most of these autophagosomes were mCherry positive in mCherry-GFP-LC3 cells. Conversely, mCherry-positive autophagosomes were rescued to green positive when treated with the acidification inhibitors chloroquine (CQ) and bafilomycin A1 (BAF), suggesting that autophagosomes fused with late endosomes or lysosomes. The co-localization of LC3-positive puncta with lysosome-associated membrane protein 1 (LAMP1) or LysoTracker confirmed that the autophagosomes fused primarily with lysosomes. Interestingly, the disruption of autophagosome formation by 3-methyladenine (3-MA) or ATG5 siRNA treatment during viral infection significantly decreased CVB3 replication. However, inhibitors of lysosomal acidification, fusion, or degradation did not affect viral replication. Therefore, autolysosomes may not be critical for viral replication in vitro.


Sujet(s)
Autophagosomes/virologie , Autophagie , Infections à virus coxsackie/physiopathologie , Entérovirus humain B/physiologie , Réplication virale , Autophagosomes/métabolisme , Infections à virus coxsackie/génétique , Infections à virus coxsackie/métabolisme , Infections à virus coxsackie/virologie , Entérovirus humain B/génétique , Cellules HEK293 , Humains , Protéine de membrane-1 associée au lysosome/génétique , Protéine de membrane-1 associée au lysosome/métabolisme , Lysosomes/métabolisme , Lysosomes/virologie
9.
Ophthalmic Surg Lasers Imaging Retina ; 47(2): 180-2, 2016 Feb.
Article de Anglais | MEDLINE | ID: mdl-26878453
11.
J Cardiovasc Transl Res ; 8(9): 536-44, 2015 Dec.
Article de Anglais | MEDLINE | ID: mdl-26525047

RÉSUMÉ

This study is to determine the therapeutic effects of Panax notoginseng saponins (PNSs) on coxsackievirus B3 (CVB3)-induced myocarditis, and whether cystathionine-γ-lyase (CSE)/hydrogen sulfide (H2S) pathway is involved. Mouse model of myocarditis was induced by CVB3 infection, and the mice were subjected to vehicle (saline) or drug treatments (sodium bisulfide (NaHS), propargylglycine (PAG), or PNSs). The results showed that there were inflammatory cell infiltrations, interstitial edemas, and elevated inflammatory cytokines, in CVB3-induced myocarditis. PAG administration increased, whereas NaHS treatment decreased the severity of the myocarditis. PNS treatment dramatically alleviated these myocardial injuries and decreased the viral messenger RNA (mRNA) expression by the enhanced expression of CSE/H2S pathway. Moreover, the therapeutic effects of PNSs on myocarditis were stronger than those of NaHS. Finally, the effect of PNSs on CSE/H2S pathway and cardiac cell protection were verified in cultured cardiac cells. PNSs may be a promising medication for viral myocarditis therapy.


Sujet(s)
Cystathionine gamma-lyase/métabolisme , Sulfure d'hydrogène/métabolisme , Myocardite/traitement médicamenteux , Myocardite/virologie , Panax notoginseng , Préparations à base de plantes/administration et posologie , Analyse de variance , Animaux , Marqueurs biologiques/métabolisme , Technique de Western , Infections à virus coxsackie/traitement médicamenteux , Infections à virus coxsackie/physiopathologie , Modèles animaux de maladie humaine , Entérovirus humain B/effets des médicaments et des substances chimiques , Entérovirus humain B/isolement et purification , Test ELISA , Humains , Mâle , Souris , Souris de lignée BALB C , Phytothérapie/méthodes , Petit ARN interférent/métabolisme , Répartition aléatoire , Réaction de polymérisation en chaine en temps réel/méthodes , Saponines/usage thérapeutique , Transduction du signal
14.
Circ Heart Fail ; 8(4): 809-18, 2015 Jul.
Article de Anglais | MEDLINE | ID: mdl-25985795

RÉSUMÉ

BACKGROUND: This study tested the hypothesis whether endoplasmic reticulum (ER) stress/C/EBP homologous protein (CHOP) signaling is linked with coxsackievirus B3 (CVB3)-induced acute viral myocarditis (AVMC) in vivo. METHODS AND RESULTS: AVMC was induced by intraperitoneal injection of 1000 tissue culture infectious dose (TCID50) of CVB3 virus in mice. In AVMC mouse hearts (n=11), ER stress and CHOP were significantly activated, and were linked to the induction of proapoptotic signaling including reduction of Bcl-2, activation of Bax and caspase 3, compared with the controls (n=10), whereas these could be markedly blocked by ER stress inhibitor tauroursodeoxycholic acid administration (n=11). Moreover, chemical inhibition of ER stress significantly attenuated cardiomyocytes apoptosis, and prevented cardiac troponin I elevation, ameliorated cardiac dysfunction assessed by both hemodynamic and echocardiographic analysis, reduced viral replication, and increased survival rate after CVB3 inoculation. We further discovered that genetic ablation of CHOP (n=10) suppressed cardiac Bcl-2/Bax ratio reduction and caspase 3 activation, and prevented cardiomyotes apoptosis in vivo, compared with wild-type receiving CVB3 inoculation (n=10). Strikingly, CHOP deficiency exhibited dramatic protective effects on cardiac damage, cardiac dysfunction, viral replication, and promoted survival in CVB3-caused AVMC. CONCLUSIONS: Our data imply the involvement of ER stress/CHOP signaling in CVB3-induced AVMC via proapoptotic pathways, and provide a novel strategy for AVMC treatment.


Sujet(s)
Infections à virus coxsackie/métabolisme , Stress du réticulum endoplasmique , Réticulum endoplasmique/métabolisme , Entérovirus humain B/pathogénicité , Myocardite/métabolisme , Myocytes cardiaques/métabolisme , Facteur de transcription CHOP/métabolisme , Animaux , Antiviraux/pharmacologie , Apoptose , Caspase-3/métabolisme , Infections à virus coxsackie/génétique , Infections à virus coxsackie/anatomopathologie , Infections à virus coxsackie/physiopathologie , Infections à virus coxsackie/prévention et contrôle , Infections à virus coxsackie/virologie , Modèles animaux de maladie humaine , Réticulum endoplasmique/effets des médicaments et des substances chimiques , Réticulum endoplasmique/virologie , Stress du réticulum endoplasmique/effets des médicaments et des substances chimiques , Entérovirus humain B/effets des médicaments et des substances chimiques , Entérovirus humain B/croissance et développement , Mâle , Souris de lignée C57BL , Souris knockout , Myocardite/génétique , Myocardite/anatomopathologie , Myocardite/physiopathologie , Myocardite/prévention et contrôle , Myocardite/virologie , Myocytes cardiaques/effets des médicaments et des substances chimiques , Myocytes cardiaques/anatomopathologie , Myocytes cardiaques/virologie , Protéines proto-oncogènes c-bcl-2/métabolisme , Transduction du signal , Acide taurochénodésoxycholique/pharmacologie , Facteur de transcription CHOP/déficit , Facteur de transcription CHOP/génétique , Réplication virale/effets des médicaments et des substances chimiques , Protéine Bax/métabolisme
15.
Mediators Inflamm ; 2014: 519528, 2014.
Article de Anglais | MEDLINE | ID: mdl-25374444

RÉSUMÉ

Myocarditis is an inflammatory disease caused by viral infection. Different subpopulations of leukocytes enter the cardiac tissue and lead to severe cardiac inflammation associated with myocyte loss and remodeling. Here, we study possible cell sources for viral replication using three compartments of the heart: fibroblasts, cardiomyocytes, and macrophages. We infected C57BL/6j mice with Coxsackievirus B3 (CVB3) and detected increased gene expression of anti-inflammatory and antiviral cytokines in the heart. Subsequently, we infected cardiac fibroblasts, cardiomyocytes, and macrophages with CVB3. Due to viral infection, the expression of TNF-α, IL-6, MCP-1, and IFN-ß was significantly increased in cardiac fibroblasts compared to cardiomyocytes or macrophages. We found that in addition to cardiomyocytes cardiac fibroblasts were infected by CVB3 and displayed a higher virus replication (132-fold increase) compared to cardiomyocytes (14-fold increase) between 6 and 24 hours after infection. At higher virus concentrations, macrophages are able to reduce the viral copy number. At low virus concentration a persistent virus infection was determined. Therefore, we suggest that cardiac fibroblasts play an important role in the pathology of CVB3-induced myocarditis and are another important contributor of virus replication aggravating myocarditis.


Sujet(s)
Infections à virus coxsackie/anatomopathologie , Infections à virus coxsackie/virologie , Entérovirus humain B/physiologie , Entérovirus humain B/pathogénicité , Myocardite/anatomopathologie , Myocardite/virologie , Myocarde/anatomopathologie , Animaux , Cellules cultivées , Infections à virus coxsackie/physiopathologie , Cytokines/génétique , Entérovirus humain B/génétique , Fibroblastes/immunologie , Fibroblastes/anatomopathologie , Fibroblastes/virologie , Expression des gènes , Génome viral , Coeur/virologie , Macrophages/immunologie , Macrophages/anatomopathologie , Macrophages/virologie , Mâle , Souris , Souris de lignée C57BL , Myocardite/physiopathologie , Myocarde/immunologie , Myocytes cardiaques/immunologie , Myocytes cardiaques/anatomopathologie , Myocytes cardiaques/virologie , Fonction ventriculaire gauche , Charge virale , Réplication virale
16.
Chin J Integr Med ; 20(12): 928-33, 2014 Dec.
Article de Anglais | MEDLINE | ID: mdl-25022551

RÉSUMÉ

OBJECTIVE: To investigate the correlations among persistent viral infection, heart function and Chinese medicine (CM) difined-syndromes in patients with dilated cardiomyopathy (DCM). METHODS: Fifty patients with DCM in the First Affiliated Hospital of Zhejiang Chinese Medical University from October 2009 to December 2011 were selected as the research subjects, and 30 healthy people were simultaneously selected as the normal control group to detect persistent viral infections after admission. The CM syndrome type and grade of heart function were then evaluated. The expression level of Coxsackie adenovirus receptor (CAR) was detected using the flow cytometry (FCM) technique, coxsackie virus RNA (CVB-RNA) using reverse transcription polymerase chain reaction (RTPCR), and the plasma brain natriuretic peptide (BNP) level with a Triage meter plus diagnosis instrument. Finally, the parameters such as left ventricular end diastolic diameter (LVEDd) and left ventricular ejection fraction (LVEF) were measured by ultrasonic cardiogram. Person correlation analysis was used for measured data, Spearman correlation analysis for rating data, and the Chi-square test for numerical data. RESULTS: CVB-RNA was positive in 22 patients (44%) with DCM, while only 6 cases (20%) were CVB-RNA-positive in the normal control group, with a significant difference between the two groups (P<0.01). The expression level of CAR was significantly elevated in the DCM group compared with the normal control group (P<0.01). In CVB-RNA-positive patients (22 cases), the expression level of CAR was significantly higher than in CVB-RNA-negative patients (28 cases; P<0.01). In the DCM patients, there was a positive correlation between the CAR expression and the BNP level (r=0.34, P<0.05), while no significant difference was found between the CAR expression and the LVEF and LVEDd (r=-0.32, 0.30, P>0.05). There was no clear correlation between virus infection and the CM syndrome types in DCM patients (r=-0.22, P>0.05). According to the sequence of syndrome types: phlegm → qi deficiency → blood stasis → hydroretention with asthenic yang (from low to high), a positive correlation was existed between the BNP levels and CM syndrome types (r=0.139, P<0.05). CONCLUSION: The expression of CAR on the surface of white cells could be used to detect persistent viral infection. The expression level of CAR and heart function in DCM patients were highly correlated. The expression level of BNP may serve as an objective index for differentiating CM syndromes for patients with DCM.


Sujet(s)
Cardiomyopathie dilatée/complications , Cardiomyopathie dilatée/physiopathologie , Infections à virus coxsackie/complications , Infections à virus coxsackie/physiopathologie , Tests de la fonction cardiaque , Médecine traditionnelle chinoise , Adulte , Sujet âgé , Cardiomyopathie dilatée/sang , Cardiomyopathie dilatée/virologie , Protéine membranaire apparentée au récepteur des coxsackievirus et adénovirus , Infections à virus coxsackie/sang , Femelle , Humains , Mâle , Adulte d'âge moyen , Peptide natriurétique cérébral/sang , ARN viral/sang , Syndrome
17.
Basic Res Cardiol ; 109(3): 408, 2014 May.
Article de Anglais | MEDLINE | ID: mdl-24691762

RÉSUMÉ

Adiponectin (APN) is an immunomodulatory adipocytokine that improves outcome in patients with virus-negative inflammatory cardiomyopathy and mice with autoimmune myocarditis. Here, we investigated whether APN modulates cardiac inflammation and injury in coxsackievirus B3 (CVB3) myocarditis. Myocarditis was induced by CVB3 infection of APN-KO and WT mice. APN reconstitution was performed by adenoviral gene transfer. Expression analyses were performed by qRT-PCR and immunoblot. Cardiac histology was analyzed by H&E-stain and immunohistochemistry. APN-KO mice exhibited diminished subacute myocarditis with reduced viral load, attenuated inflammatory infiltrates determined by NKp46, F4/80 and CD3/CD4/CD8 expression and reduced IFNß, IFNγ, TNFα, IL-1ß and IL-12 levels. Moreover, myocardial injury assessed by necrotic lesions and troponin I release was attenuated resulting in preserved left ventricular function. Those changes were reversed by APN reconstitution. APN had no influence on adhesion, uptake or replication of CVB3 in cardiac myocytes. In acute CVB3 myocarditis, cardiac viral load did not differ between APN-KO and WT mice. However, APN-KO mice displayed an enhanced acute immune response, i.e. increased expression of myocardial CD14, IFNß, IFNγ, IL-12, and TNFα resulting in increased cardiac infiltration with pro-inflammatory M1 macrophages and activated NK cells. Up-regulation of cardiac CD14 expression, type I and II IFNs and inflammatory cell accumulation in APN-KO mice was inhibited by APN reconstitution. Our observations indicate that APN promotes CVB3 myocarditis by suppression of toll-like receptor-dependent innate immune responses, polarization of anti-inflammatory M2 macrophages and reduction of number and activation of NK cells resulting in attenuated acute anti-viral immune responses.


Sujet(s)
Adiponectine/métabolisme , Infections à virus coxsackie/métabolisme , Entérovirus humain B/immunologie , Myocardite/métabolisme , Myocarde/métabolisme , Adiponectine/déficit , Adiponectine/génétique , Animaux , Animaux nouveau-nés , Cellules cultivées , Infections à virus coxsackie/génétique , Infections à virus coxsackie/immunologie , Infections à virus coxsackie/anatomopathologie , Infections à virus coxsackie/physiopathologie , Infections à virus coxsackie/virologie , Modèles animaux de maladie humaine , Entérovirus humain B/génétique , Entérovirus humain B/pathogénicité , Immunité innée , Médiateurs de l'inflammation/métabolisme , Cellules tueuses naturelles/immunologie , Cellules tueuses naturelles/métabolisme , Cellules tueuses naturelles/virologie , Macrophages/immunologie , Macrophages/métabolisme , Macrophages/virologie , Souris , Souris de lignée C57BL , Souris knockout , Myocardite/génétique , Myocardite/immunologie , Myocardite/anatomopathologie , Myocardite/physiopathologie , Myocardite/virologie , Myocarde/immunologie , Myocarde/anatomopathologie , Nécrose , Rats , Rat Wistar , Récepteurs de type Toll/métabolisme , Fonction ventriculaire gauche , Charge virale
19.
Cardiovasc Ther ; 32(3): 113-9, 2014 Jun.
Article de Anglais | MEDLINE | ID: mdl-24533719

RÉSUMÉ

INTRODUCTION: Myocarditis is induced by coxsackievirus B3 (CVB3). Myocardial inflammation is tied to the activation of coagulation. Coagulation factor (F) Xa, a central player in coagulation, activates matrix metalloproteinases (MMP), which modulate the remodeling. AIMS: In this study, we investigated the effects of pharmacological FXa inhibition on myocardial function, inflammation, and remodeling during a CVB3-induced myocarditis. METHODS AND RESULTS: Immune cells and matrix proteins were detected by immunohistochemistry. The expression of cytokines was measured by real-time PCR and the activity of MMP-2 by zymography. Left ventricular function was analyzed using microconductance pressure catheter. Treatment with the FXa inhibitor fondaparinux led to an improved left ventricular function in CVB3-induced mice compared to saline-treated controls (dPdtmax: fondaparinux 4632 ± 499.6 vs. saline 3131 ± 374.0 [mmHg/s], P = 0.0503; SV: fondaparinux 33.19 ± 4.893 vs. saline 19.32 ± 2.236 [µL], P < 0.118; CO: fondaparinux 15124 ± 2183 vs. saline 8088 ± 1035 [µL/min], P < 0.05). Therapy with fondaparinux reduced the activity of MMP-2 (fondaparinux 1.208 ± 0.1247 vs. saline 1.565 ± 0.05476, P < 0.05). The collagen type I/III ratio as well as the expression of TIMP-1 was comparable in both infection groups postinfectionem (p.i.), despite an increased infiltration of macrophages into the hearts of mice treated with fondaparinux 8 days p.i. (CD68+: fondaparinux 494.2 ± 64.73 vs. saline 306.9 ± 43.73 [cells/mm(2) ], P < 0.05). Anti-inflammatory CD206-positive M2-type macrophages were increased in the infected hearts after fondaparinux treatment (CD206+: fondaparinux 182.1 ± 18.18 vs. saline 111.6 ± 21.07 [cells/mm(2) ], P < 0.05), whereas CD80-positive M1-type macrophages were comparable in both groups. CONCLUSION: In conclusion, selective inhibition of FXa improves the left ventricular function during CVB3-induced myocarditis and seems to be associated with an improved myocardial remodeling.


Sujet(s)
Infections à virus coxsackie/traitement médicamenteux , Entérovirus humain B/pathogénicité , Inhibiteurs du facteur Xa/pharmacologie , Facteur Xa/métabolisme , Myocardite/traitement médicamenteux , Polyosides/pharmacologie , Fonction ventriculaire gauche/effets des médicaments et des substances chimiques , Remodelage ventriculaire/effets des médicaments et des substances chimiques , Animaux , Infections à virus coxsackie/sang , Infections à virus coxsackie/physiopathologie , Infections à virus coxsackie/virologie , Cytokines/génétique , Cytokines/métabolisme , Modèles animaux de maladie humaine , Fondaparinux , Médiateurs de l'inflammation/métabolisme , Mâle , Matrix metalloproteinase 2/métabolisme , Souris de lignée C57BL , Myocardite/sang , Myocardite/physiopathologie , Myocardite/virologie , ARN messager/métabolisme , Charge virale
20.
Article de Chinois | MEDLINE | ID: mdl-25571644

RÉSUMÉ

OBJECTIVE: To explore the apoptotic pathway mediated by endoplasmic reticulum stress in the mouse myocardium with heart failure induced by acute viral myocarditis caused by B-3 Coxsackie virus. METHODS: Forty BALB/c male mice were randomly divided into 2 groups (n = 20): the control group and the virus infection group. The BALB/c mouse myocarditis was induced by B-3 Coxsackie virus and the mouse behavior was observed conventionally. All the mice were sacrificed on day 7 and the changes of left ventricular pressure (LVP) and the rate of change of left ventricular pressure (LV dp/dt) were measured. The cardiomyocytic apoptosis was analyzed by TUNEL method and the mRNA expression level of endoplasmic reticulum haperones glucose-regulated protein (GRP)78 and GRP94 was detected by RT-PCR. RESULTS: (1) Compared with those of control group, the parameters of cardiac hemodynamics in the virus infection group were significantly decreased (P < 0.01); (2) Compared with that of control group, myocardial apoptosis was significantly increased in the myocardial cells from mice with heart failure induced by acute viral myocarditis (P < 0.01); (3) The mRNA expression level of GRP78 and GRP94 were increased significantly in the virus infection group compared with the control group. CONCLUSION: These findings suggest the endoplasmic reticulum stress may mediate the apoptosis of myocardial cells in the mice myocardium of heart failure induced by acute viral myocarditis caused by B-3 Coxsackie virus.


Sujet(s)
Apoptose , Infections à virus coxsackie/physiopathologie , Stress du réticulum endoplasmique , Défaillance cardiaque/virologie , Myocardite/virologie , Myocytes cardiaques/cytologie , Animaux , Chaperonne BiP du réticulum endoplasmique , Coeur/physiopathologie , Défaillance cardiaque/physiopathologie , Protéines du choc thermique/métabolisme , Mâle , Glycoprotéines membranaires/métabolisme , Souris , Souris de lignée BALB C , Myocardite/physiopathologie , Myocarde/anatomopathologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...